From 1Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California; 2Female Pelvic Medicine and Reconstructive Surgery, Department of Reproductive Medicine, University of California, San Diego, California; and 3Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, Kaiser Permanente, San Diego, California.
Funded by the National Institutes of Health, NICHD R01 HD41113, and Kaiser Permanente Direct Community Benefit funds.
Presented at the Society for Epidemiologic Research and the Canadian Society for Epidemiology and Biostatistics, Toronto, Ontario, Canada, June 27–30, 2005, and the 26th Annual Meeting of the American Urogynecology Society, Atlanta, Georgia, September 15–17, 2005.
Corresponding author: Emily S. Lukacz, MD, MAS, 9350 Campus Point Drive, #0974, La Jolla, CA 92037; e-mail: [email protected].
Financial Disclosure Dr. Lukacz is a consultant and speaker for Pfizer (New York, NY) and a speaker for Novartis (Basel, Switzerland). Dr. Luber is a consultant and speaker for Pfizer, Watson Pharmaceuticals (Corona, CA), and Astellas Pharmaceuticals (Tokyo, Japan). The other authors have no potential conflicts of interest to disclose.